Peptidoglycan (PGN) is a macrophage activator from Gram-positive bacteria.
PGN activates cells of hemopoietic origin through CD14 since: (i) PGN-unres
ponsive CD14-negative cells become PGN-responsive after transfection with C
D14 and expression of membrane CD14; (ii) PGN binds to CD14 with high affin
ity; and (iii) anti-CD14 mAbs inhibit both binding of PGN to CD14 and activ
ation of CD14-positive cells by PCN. However, there are several differences
in the function of CD14 as PGN and LPS receptor: (i) the kinetics of bindi
ng are different; (ii) the affinity of binding in the absence of LPS-bindin
g protein (LBP) is higher for PGN than LPS; (iii) LBP does not increase the
affinity of binding of PGN to CD14 and does not enhance cell activation by
PGN tin contrast to LPS); (iv) the regions of CD14 needed for binding and
activation are partially similar and partially different for PGN and LPS; (
v) sCD14:PGN complexes, in contrast to sCD14:LPS complexes, do not activate
CD14-negative cells; (vi) PGN, in contrast to LPS, does not activate CHO c
ells expressing mCD14; and (vii) PGN and LPS induce differential activation
of MAP kinases, but activate similar transcription factors (NF-kappa B, AT
F1/CREB, and AP-1).